CardiAMP cell therapy-treated patients had 37% relative risk reduction in heart death equivalent (death, heart transplant, left ventricular assist device implantation) and 9% relative risk reduction ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), the Breast International Group (BIG), Institut Jules Bordet Clinical Trials Support ...
– Itovebi TM (inavolisib)-based regimen demonstrated a statistically significant and clinically meaningful benefit, reducing the risk of disease worsening or death by 57% compared with palbociclib and ...
Patients with advanced pathologic stage, a higher number of positive lymph nodes, and positive surgical margins had the highest risks of dying from prostate cancer. Lymph node positive (pN1) prostate ...
In a cohort of patients with clinically node-positive prostate cancer matched by other-cause mortality, radiation therapy was significantly associated with an 86% higher risk of dying from prostate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback